CLNN
Clene Inc.Company Information
- Company Name
- Clene Inc.
- CIK
- CIK0001822791
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- CLNN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- CLNN
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-01-13
- Last sale
- 2026-05-12
- Shares purchased (TTM)
- 33,333
- Shares sold (TTM)
- 401,263
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 3,163,465
- Shares outstanding
- 12,382,702
- Ownership
- 25.55%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- -7.00%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Cash Equivalents At Carrying Value | 10 | 6 | 5 | 8 | 7 | 10 | 12 | 15 | 22 | 22 | 29 | 42 | ||||||
| Marketable Securities Current | - | - | - | - | - | - | 0 | 0 | 0 | 6 | 6 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Accounts Receivable Net Current | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets Current | 15 | 13 | 9 | 13 | 12 | 15 | 16 | 20 | 28 | 32 | 39 | 46 | ||||||
| Inventory Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 5 | 7 | 4 | 5 | 5 | 5 | 4 | 5 | 6 | 4 | 4 | 4 | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Right Of Use Asset | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 5 | 6 | 6 | 6 | 7 | 7 | 7 | 8 | 8 | 9 | 9 | 10 | ||||||
| Assets | 23 | 22 | 18 | 22 | 22 | 25 | 27 | 32 | 40 | 45 | 52 | 60 | ||||||
| Accounts Payable Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 2 | ||||||
| Accrued Liabilities Current | 2 | 3 | 5 | 5 | 5 | 5 | 8 | 7 | 6 | 4 | 4 | 3 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 5 | 7 | 11 | 8 | 8 | 11 | 10 | 24 | 28 | 26 | 25 | 15 | ||||||
| Notes Payable Current | - | - | - | - | - | 3 | 0 | 11 | 20 | 15 | 15 | 10 | ||||||
| Mediumterm Notes Current | 0 | 1 | 2 | 1 | 0 | - | 0 | - | - | - | - | - | ||||||
| Convertible Notes Payable Current | 0 | 1 | 2 | 1 | - | - | 0 | - | - | - | - | - | ||||||
| Finance Lease Liability Current | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Convertible Debt Current | - | - | - | - | - | - | 0 | 0 | 0 | 5 | 5 | - | ||||||
| Operating Lease Liability Noncurrent | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Long Term Notes Payable | 5 | 5 | 4 | 5 | 5 | 2 | 5 | 2 | 2 | 2 | 2 | 7 | ||||||
| Convertible Debt Noncurrent | - | - | - | - | - | - | 11 | - | - | - | 5 | - | ||||||
| Liabilities | 48 | 40 | 36 | 35 | 31 | 30 | 36 | 36 | 41 | 41 | 39 | 39 | ||||||
| Derivative Liabilities Noncurrent | - | - | - | - | - | - | - | 1 | 1 | 3 | 1 | 2 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | -25 | -19 | -18 | -12 | -9 | -5 | -9 | -4 | -1 | 4 | 13 | 21 | ||||||
| Additional Paid In Capital | 305 | 297 | 291 | 287 | 282 | 278 | 273 | 264 | 260 | 258 | 256 | 254 | ||||||
| Retained Earnings Accumulated Deficit | -330 | -316 | -308 | -299 | -290 | -283 | -282 | -269 | -261 | -254 | -243 | -233 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities And Stockholders Equity | 23 | 22 | 18 | 22 | 22 | 25 | 27 | 32 | 40 | 45 | 52 | 60 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 600 | 600 | 600 | 600 | 600 | 600 | 600 | 600 | 600 | 300 | 300 | 300 | ||||||
| Common Stock Shares Issued | 13 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 6 | 6 | 6 | ||||||
| Shares Outstanding | 13 | 12 | 11 | 10 | 9 | 9 | 8 | 7 | 6 | 6 | 6 | 6 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialClene Inc. (CLNN) — SEC Financial Statements & Analysis
Clene Inc. (CLNN) is a pharmaceutical preparations company, incorporated in DE. Clene Inc. trades on Nasdaq as: CLNN. Clene Inc. (CLNN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Clene Inc. carries a market cap of $76.28M, a P/E ratio of -1.93x, a P/B ratio of -3.08x, a P/S ratio of 387.20x, an enterprise value of $71.92M, and an EV/EBITDA multiple of -3.76x. On profitability, it posts a gross margin of 78.86%, an operating margin of -10431.98%, a net margin of -20059.90%, a Return on Equity (ROE) of 237.15%, a Return on Assets (ROA) of -174.99%, and a Return on Invested Capital (ROIC) of -10148.17%. Per share, it reports EPS of $-3.19, free cash flow per share of $-1.29, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -31.12% year-over-year, net income growth of 33.03% year-over-year, and EPS growth of 2.32% year-over-year. On the balance sheet, it maintains a current ratio of 3.07x, a quick ratio of 2.00x, working capital of $10.06M, a debt-to-equity ratio of -1.93x, a debt ratio of 2.08, an interest coverage ratio of -7.13x, free cash flow of $-15.95M (TTM), and net debt of $-4.36M. Figures sourced from SEC EDGAR.
- Market Cap
- $76.28M
- P/E TTM
- -1.93x
- EPS TTM
- $-3.19
- P/B TTM
- -3.08x
- ROE TTM
- 237.15%
- ROA TTM
- -174.99%
- Debt To Equity
- -1.93x
- Free Cash Flow TTM
- $-15.95M
- Net Revenue TTM Growth 1Y
- -31.12%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Clene Inc. in?
Clene Inc. (CLNN) operates in the Pharmaceutical Preparations industry.
What exchange does CLNN trade on?
Clene Inc. (CLNN) trades on the Nasdaq.
Where is Clene Inc. incorporated?
Clene Inc. is incorporated in DE.
When was Clene Inc. (CLNN)'s most recent SEC filing?
Clene Inc. (CLNN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is CLNN's market cap?
Clene Inc. (CLNN) has a market capitalization of $76.28M as of 2026-06-30.
What is CLNN's EPS (earnings per share)?
Clene Inc. (CLNN)'s trailing twelve month EPS is $-3.19 as of 2026-06-30.
What is CLNN's ROE (return on equity)?
Clene Inc. (CLNN)'s trailing twelve month Return on Equity (ROE) is 237.15% as of 2026-06-30.
What is CLNN's ROA (return on assets)?
Clene Inc. (CLNN)'s trailing twelve month Return on Assets (ROA) is -174.99% as of 2026-06-30.
What is CLNN's ROIC (return on invested capital)?
Clene Inc. (CLNN)'s trailing twelve month Return on Invested Capital (ROIC) is -10148.17% as of 2024-03-31.
What is CLNN's EV/EBITDA?
Clene Inc. (CLNN)'s trailing twelve month EV/EBITDA is -3.76x as of 2026-06-30.